Treven And Forest Labs Reach Deal To Develop TRV027 To Treat Acute Heart ... RTT News Trevena said TRV027 is an experimental intravenous drug for the treatment of acute decompensated heart failure (ADHF), currently in mid-stage clinical trials. It is a novel beta-arrestin biased ligand of the angiotensin II type 1 receptor (AT1R) that ... Forest Labs Bets Up To $460M on Trevena Heart Failure Drug Trevena Raises $60M Series C, Strikes $430M Option Deal With Forest Labs Trevena lands $430M Forest deal, $60M venture round as heart drug heads to ... |
